Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161294 | 1.00 | CYP1A2 (0.43) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL27906375 | 1.00 | CYP1A2 (0.43) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2248721 | 0.90 | CYP1A2 (0.50) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28486150 | 0.89 | GRM8 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28486157 | 0.89 | GRM8 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28464434 | 0.86 | GRM8 (0.44) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28475140 | 0.82 | GRM8 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28475131 | 0.82 | GRM8 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL28666295 | 0.81 | CYP1A2 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10523165 | 0.81 | CYP1A2 (0.52) | CYP1A2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119000770-A | Estimation method of non-ideal imaging factor of magnetic resonance spectrum | 中国人民解放军联勤保障部队第九〇九医院 | 2024-11-22 | — | — | CN | claimed |
| CN-117890510-A | Construction and determination method of early prostate cancer diagnosis marker model | 安徽省宿州市立医院 | 2024-04-16 | — | — | CN | claimed |
| CN-114965800-A | Renal clear cell carcinoma biomarker and application thereof in early screening | 山西医科大学 | 2022-08-30 | — | — | CN | claimed |
| CN-106537145-A | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| CN-119769618-A | Method for improving sheep slaughtering performance and mutton delicate flavor | 内蒙古农业大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-114096264-B | Method for preparing PSMA conjugate | 因多塞特股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114245877-B | Contact lens and mould for preparing same | 大元制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| CN-119000770-A | Estimation method of non-ideal imaging factor of magnetic resonance spectrum | 中国人民解放军联勤保障部队第九〇九医院 | 2024-11-22 | — | — | CN | disclosed |
| CN-118785925-A | Marker precursors and radiotracers with three or more targeting vectors for use in diagnostic nuclear medicine therapies | 原子治疗有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-114364405-B | Prostate Specific Membrane Antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutics | 五一一制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118130682-A | High-sensitivity analysis method for selectively enriching important biomarkers of brain tissue | 上海交通大学 | 2024-06-04 | — | — | CN | disclosed |
| EP-2916831-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT INFLAMMATION ASSOCIATED CONDITIONS | 3E Therapeutics Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9044449-B2 | X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of CNS inflammation and inflammation associated conditions | 3E THERAPEUTICS CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140151548-A1 | MATRIX FOR MALDI MASS SPECTROMETRY AND MALDIMASS SPECTROMETRY METHOD | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2014-06-05 | — | — | US | disclosed |
| WO-2014074744-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT INFLAMMATION ASSOCIATED CONDITIONS | LASSER ELLIOTT C (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2730918-A1 | MATRIX FOR MALDI MASS SPECTROMETRY | Kyushu University National University Corporation (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-20140079811-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | LASSER FAMILY PARTNERSHIP LLP | 2014-03-20 | — | — | US | disclosed |
| US-20130071490-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | LASSER FAMILY PARTNERSHIP LLP | 2013-03-21 | — | — | US | disclosed |
| JP-2005036008-A | INHIBITOR FOR NEURO-CARBOXYPEPTIDASES ACTIVITY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | SLOAN-KETTERING INST FOR CANCER RESEARCH | 2005-02-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071490-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | CHI3L2, CHI3L1, CCR1 | CYP1A2 3205/4885GRM8 523/4885GRM6 826/4885 |
| US-20140079811-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | CHI3L2, CHI3L1, CCR1 | CYP1A2 3205/4885GRM8 523/4885GRM6 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.